Olivier Catalani

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Marek Trněný, David Belada et al. · Journal of Clinical Oncology · 2017 · 424 citations

Medicine, Hematology, Oncology +12

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Christophe Schmitt, Joanne I. Adamkewicz, Jin Xu et al. · Thrombosis and Haemostasis · 2020 · 96 citations · Full text

Medicine, Hematology, Pharmacology +15

Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study

Antonio Salar, Irit Avivi, Beate Bittner et al. · Journal of Clinical Oncology · 2014 · 93 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study

Claude Négrier, Johnny Mahlangu, Michaela Lehle et al. · The Lancet Haematology · 2023 · 83 citations · Full text

Medicine, Hematology, Pharmacotherapy +9

MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia

Pau Montesinos, Benjamin M. Beckermann, Olivier Catalani et al. · Future Oncology · 2020 · 78 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15